Ermelinda Santos Silva

Prof. Dr. Ermelinda Santos Silva

orcid

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in The American Journal of Human Genetics
Verified
Journal Article
Closed access
ASAnna-Barbara Stittrich
Anna-Barbara Stittrich
ALAnna Lehman
Anna Lehman
DBDale L. Bodian
Dale L. Bodian
JAJustin Ashworth
Justin Ashworth
ZZZheyuan Zong
Zheyuan Zong
MPMillan S. Patel
Millan S. Patel

1 February 1996 in The Journal of Pediatrics
Verified
Journal Article
Closed access
ESErmelinda Santos Silva
Ermelinda Santos Silva
JSJacques Sarles
Jacques Sarles
JBJean Paul Buts
Jean Paul Buts
ESEtienne M Sokal
Etienne M Sokal

1 January 2000 in Journal of Hepatology
Verified
Journal Article
Closed access
ESErmelinda Santos Silva
Ermelinda Santos Silva
SLSerge Lumbroso
Serge Lumbroso
MMMargarida Medina
Margarida Medina
YGYves Gillerot
Yves Gillerot
CSCharles Sultan
Charles Sultan
ESEtienne M Sokal
Etienne M Sokal

1 November 1995 in Transplantation
Verified
Journal Article
Closed access
ESEtienne M Sokal
Etienne M Sokal
ESErmelinda Santos Silva
Ermelinda Santos Silva
DHDominique Hermans
Dominique Hermans
RRRaymond Reding
Raymond Reding
JGJean de Ville de Goyet
Jean de Ville de Goyet
JOJean Bernard Otte
Jean Bernard Otte
Hyperbilirubinemia in Crigler-Najjar disease type I (CN) can be partially controlled by daily phototherapy, but these children remain at permanent risk of developing brain damage due to kernicterus. Because liver transplantation is the only available curative treatment for liver-based inborn errors of metabolism, orthotopic liver transplantation (OLT) was performed in six patients with CN. Mean age at surgery was 52.5 months (range 27 to 100). Despite a mean daily phototherapy of 12.4 +/- 0.8 hr, mean bilirubin of the 6 patients was 388 microM/L (range 175 to 703) before OLT; one of them was also being treated with tin-protoporphyrin. All 6 had elevated AST/ALT, ranging from 1.4 to 6 times upper normal values. Complications occurred in three patients after OLT, including miliary tuberculosis in one, graft rejection and retransplantation in one, and hepatic artery thrombosis in one. All patients survive with normal serum bilirubin level (follow up 6 to 116 months). Four have normal enzymes on post-OLT follow-up (30 to 95 months), follow a normal education program, and have a normal social life. One recently transplanted patient has progressively normalizing liver function tests 6 months after OLT. One patient transplanted at 8 y.o. (now 116 months post-OLT) has moderate neurological delay due to pretransplant kernicterus, and posttransplant chronic persistent hepatitis. Our series shows that OLT cures hyperbilirubinemia in CN patients, with an excellent survival prospect. The procedure should be decided upon before neurological sequelae occur, since these persist after transplantation.

15 January 2020 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
JSJulia von Schnurbein
Julia von Schnurbein
CAClaire Adams
Claire Adams
BABaris Akinci
Baris Akinci
GCGiovanni Ceccarini
Giovanni Ceccarini
MDMaria Rosaria D’aPice
Maria Rosaria D’aPice
MWMartin Wabitsch
Martin Wabitsch
Background: Lipodystrophy syndromes comprise a group of extremely rare and heterogeneous diseases characterized by a selective loss of adipose tissue in the absence of nutritional deprivation or catabolic state. Because of the rarity of each lipodystrophy subform, research in this area is difficult and international co-operation mandatory. Therefore, in 2016, the European Consortium of Lipodystrophies (ECLip) decided to create a registry for patients with lipodystrophy. Results: The registry was build using the information technology Open Source Registry System for Rare Diseases in the EU (OSSE), an open-source software and toolbox. Lipodystrophy specific data forms were developed based on current knowledge of typical signs and symptoms of lipodystrophy. The platform complies with the new General Data Protection Regulation (EU) 2016/679 by ensuring patient pseudonymization, informational separation of powers, secure data storage and security of communication, user authentication, person specific access to data, and recording of access granted to any data. Inclusion criteria are all patients with any form of lipodystrophy (with the exception of HIV-associated lipodystrophy). So far 246 patients from nine centres (Amsterdam, Bologna, Izmir, Leipzig, Münster, Moscow, Pisa, Santiago de Compostela, Ulm) have been recruited. With the help from the six centres on the brink of recruitment (Cambridge, Lille, Nicosia, Paris, Porto, Rome) this number is expected to double within the next one or 2 years. Conclusions: A European registry for all patients with lipodystrophy will provide a platform for improved research in the area of lipodystrophy. All physicians from Europe and neighbouring countries caring for patients with lipodystrophy are invited to participate in the ECLip Registry. Study registration: ClinicalTrials.gov (NCT03553420). Registered 14 March 2018, retrospectively registered.

1 January 2006 in Blood Cells, Molecules, and Diseases
Verified
Journal Article
Closed access
Elisio CostaElisio Costa
Elisio Costa
EVEmília Vieira
Emília Vieira
MMMarcia Martins
Marcia Martins
JSJorge Saraiva
Jorge Saraiva
ECEugénia Cancela
Eugénia Cancela
RSRosário Santos
Rosário Santos